Participant flow

A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) · Source last updated 2024-06-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)

   id

   FG000

   title

   R/R ENKTL

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         14

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         40

      type

      Lack of Efficacy

   4. reasons

      1. group Id

         FG000

         num Subjects

         10

      type

      Withdrawal by Subject

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Dosing delayed over 9 weeks

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Achieved CR and completed 2 years of treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         80

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         13

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         67

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice